Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARL 3 extension study of lurasidone versus quetiapine XR in schizophrenia
ISRCTN44297014Phase 3Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Dec 2008
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Lurasidone with Quetiapine XR (2 arms). Primary endpoints: Time to relapse of psychotic symptoms, Proportion of subjects with adverse events and 2 more. Started Dec 2008; status: completed.
02
Drugs
lurasidonequetiapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on ISRCTN44297014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN44297014.